Insider Selling: DexCom (NASDAQ:DXCM) Director Sells $296,520.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 4,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the sale, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. This trade represents a 7.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

Shares of DXCM stock opened at $72.47 on Friday. The stock has a market capitalization of $27.96 billion, a price-to-earnings ratio of 30.97, a PEG ratio of 1.13 and a beta of 1.45. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company’s 50-day simple moving average is $67.07 and its 200-day simple moving average is $67.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the company earned $0.32 earnings per share. DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. Equities analysts anticipate that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

Institutional Trading of DexCom

Several hedge funds have recently made changes to their positions in DXCM. Vanguard Group Inc. grew its stake in DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after buying an additional 1,133,638 shares during the last quarter. Geode Capital Management LLC increased its position in DexCom by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after buying an additional 42,411 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in DexCom by 6.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after buying an additional 516,526 shares during the last quarter. Norges Bank bought a new stake in DexCom in the fourth quarter valued at $483,356,000. Finally, Invesco Ltd. boosted its holdings in shares of DexCom by 14.8% during the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after acquiring an additional 686,228 shares during the period. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DXCM. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. TD Cowen restated a “buy” rating and set a $95.00 price objective (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Benchmark started coverage on shares of DexCom in a report on Monday, May 11th. They issued a “buy” rating and a $77.00 price objective for the company. Barclays reissued an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of DexCom in a research report on Monday, June 1st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $84.83.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.